Vemurafenib was discontinued, and therapy with ipilimumab (3 mg/kg body weight) was started.
Treatment with TT-232 (0.2 – 1.5 mg kg−1 body weight) was started on day 31 after thymectomy.
Control mice received only the solvent in aliquots of 0.2 ml s.c. Treatment with TT-232 (1 mg kg−1 body weight) was started on day 31 after thymectomy.
In July 2001, systemic acitretin at 0.5 mg/kg body weight was started, but stopped within 6 weeks due to elevated serum lipids.
A primed infusion of d-[6,6-d2]glucose (3.6 mg/kg body weight × [fasting plasma glucose/90]) followed by a continuous infusion (0.036 mg/min × kg body weight) was started to determine EGP (15).
Tumor size and body weight were recorded before starting the treatment and at 5-days intervals for 20 days.
After 1 wk recovery, daily food intake and body weight measurements were started 1 d before peptide treatment.
Estimated heritabilities for starting body weight were comparable to previous estimates in turkeys [ 7, 11].
Serum glucose levels and body weight were monitored at the start and end of the experiment.
Tumor size and body weight were measured before and 3 days after the start of treatment.
